^
    Apply
    A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE) (NCT04939610)
    Phase 1/2
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    07/30/2021
    Primary completion :
    06/30/2026
    Completion :
    06/30/2028
    FAP
    |
    FAP expression
    |
    AAA614
    89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma (ZOLAR) (NCT06537596)
    Phase 1
    Telix Pharmaceuticals (Innovations) Pty Ltd
    Recruiting
    Last update posted :
    12/19/2024
    Initiation :
    10/31/2024
    Primary completion :
    03/01/2026
    Completion :
    08/01/2026
    PDGFRA
    |
    FOLR1 expression
    |
    Lartruvo (olaratumab)
    Study of the Theranostic Pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to Identify and Treat Subjects with GPC3+ Unresectable HCC (NCT06726161)
    Phase 1
    RayzeBio, Inc.
    Recruiting
    Last update posted :
    12/10/2024
    Initiation :
    12/01/2024
    Primary completion :
    03/01/2029
    Completion :
    01/01/2031
    GPC3
    A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea (NCT04946305)
    Phase N/A
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    06/14/2024
    Initiation :
    05/10/2022
    Primary completion :
    07/08/2024
    Completion :
    07/08/2024
    SSTR
    |
    SSTR positive
    |
    Lutathera (lutetium Lu 177 dotatate)
    Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs (NCT04711135)
    Phase 2
    Advanced Accelerator Applications
    Active, not recruiting
    Last update posted :
    06/14/2024
    Initiation :
    08/31/2022
    Primary completion :
    03/12/2024
    Completion :
    05/07/2029
    SSTR
    |
    SSTR Expression
    |
    Lutathera (lutetium Lu 177 dotatate)
    Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors (ETCTN 10388) (NCT04234568)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/13/2024
    Initiation :
    07/20/2020
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    SSTR
    |
    SSTR Expression
    |
    Lutathera (lutetium Lu 177 dotatate) • Triapine (3-AP)
    LUTATHERA Injection General Use Result Survey (NCT05844332)
    Phase N/A
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    06/11/2024
    Initiation :
    12/17/2021
    Primary completion :
    01/31/2027
    Completion :
    01/31/2027
    SSTR
    |
    SSTR positive
    |
    Lutathera (lutetium Lu 177 dotatate)
    Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones (NCT04090398)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/05/2024
    Initiation :
    08/04/2020
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    HER-2 • ER • PGR
    |
    ER positive • HR positive • HER-2 negative • ER negative • PGR negative
    |
    paclitaxel • Xofigo (radium Ra-223 dichloride)
    Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors (NCT05247905)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    03/16/2022
    Primary completion :
    03/31/2028
    Completion :
    10/01/2033
    SSTR
    |
    temozolomide • capecitabine • Lutathera (lutetium Lu 177 dotatate)
    HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Single Domain Antibody (NCT04674722)
    Phase 1
    Shanghai General Hospital, Shanghai Jiao Tong U...
    Recruiting
    Last update posted :
    05/17/2024
    Initiation :
    08/24/2020
    Primary completion :
    03/08/2024
    Completion :
    09/30/2024
    HER-2
    |
    HER-2 overexpression • HER-2 expression
    Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis (COMRADE) (NCT03317392)
    Phase 1/2
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    05/17/2024
    Initiation :
    02/04/2019
    Primary completion :
    11/30/2024
    Completion :
    11/30/2024
    HRD • CD4
    |
    HRD
    |
    Lynparza (olaparib) • Xofigo (radium Ra-223 dichloride)
    Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG (NCT05610891)
    Phase 1
    Cellectar Biosciences, Inc.
    Recruiting
    Last update posted :
    05/16/2024
    Initiation :
    10/01/2023
    Primary completion :
    05/01/2026
    Completion :
    09/01/2026
    CD34
    |
    iopofosine I-131 (CLR 131)
    Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2) (NCT03972488)
    Phase 3
    Advanced Accelerator Applications
    Active, not recruiting
    Last update posted :
    05/15/2024
    Initiation :
    01/22/2020
    Primary completion :
    07/20/2023
    Completion :
    10/29/2027
    SSTR
    |
    SSTR Expression
    |
    Lutathera (lutetium Lu 177 dotatate) • octreotide acetate
    A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab (NCT05142696)
    Phase 1/2
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    05/03/2024
    Initiation :
    07/13/2022
    Primary completion :
    05/05/2025
    Completion :
    05/03/2028
    SSTR
    |
    SSTR positive
    |
    Tecentriq (atezolizumab) • carboplatin • Tevimbra (tislelizumab-jsgr) • etoposide IV • Lutathera (lutetium Lu 177 dotatate)
    Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver (NCT04544098)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    05/02/2024
    Initiation :
    09/02/2020
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    SSTR
    |
    SSTR positive • SSTR Expression
    |
    Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)
    Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors (NCT05868174)
    Phase 1
    Telix Pharmaceuticals (Innovations) Pty Limited
    Recruiting
    Last update posted :
    05/01/2024
    Initiation :
    05/23/2023
    Primary completion :
    12/01/2024
    Completion :
    12/01/2026
    CA9
    |
    peposertib (M3814) • 177Lu-DOTA-girentuximab (TLX250) • Rencarex (girentuximab)
    [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (NeoRay) (NCT03872778)
    Phase 1/2
    Advanced Accelerator Applications
    Recruiting
    Last update posted :
    04/25/2024
    Initiation :
    07/24/2019
    Primary completion :
    11/24/2025
    Completion :
    12/01/2026
    HER-2 • BRCA1 • BRCA2 • CDK4
    |
    BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative
    |
    AAA603
    Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer (iPRRT) (NCT05583708)
    Phase 2
    Weill Medical College of Cornell University
    Recruiting
    Last update posted :
    04/17/2024
    Initiation :
    08/03/2023
    Primary completion :
    09/01/2026
    Completion :
    09/01/2026
    SSTR
    |
    Keytruda (pembrolizumab) • Lutathera (lutetium Lu 177 dotatate)
    NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial (NCT06066437)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    04/01/2024
    Initiation :
    03/29/2024
    Primary completion :
    06/30/2025
    Completion :
    06/30/2026
    FOLH1
    |
    FOLH1 expression
    |
    Firmagon (degarelix)
    Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy (NCT04082520)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    03/29/2024
    Initiation :
    04/08/2020
    Primary completion :
    09/04/2024
    Completion :
    09/04/2025
    SSTR
    |
    SSTR Expression
    |
    Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)
    A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors (NCT05706129)
    Phase 1/2
    Debiopharm International SA
    Recruiting
    Last update posted :
    03/29/2024
    Initiation :
    03/14/2023
    Primary completion :
    01/01/2026
    Completion :
    01/01/2027
    EGFR
    |
    ITM-91
    Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors (NCT06016855)
    Phase 4
    Vanderbilt-Ingram Cancer Center
    Recruiting
    Last update posted :
    03/28/2024
    Initiation :
    04/30/2024
    Primary completion :
    02/28/2027
    Completion :
    02/28/2028
    SSTR
    |
    Lutathera (lutetium Lu 177 dotatate)
    Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma (NCT02342782)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    03/19/2024
    Initiation :
    06/08/2020
    Primary completion :
    09/18/2020
    Completion :
    12/31/2024
    ALK • CD34
    |
    cytarabine • etoposide IV • etoposide oral • carmustine • melphalan • Simulect (basiliximab)
    Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma (NCT01476839)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    03/19/2024
    Initiation :
    11/09/2012
    Primary completion :
    07/24/2021
    Completion :
    12/31/2024
    CD34
    |
    cytarabine • etoposide IV • carmustine • melphalan • Simulect (basiliximab)
    EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T (VIOLET) (NCT05521412)
    Phase 1/2
    Peter MacCallum Cancer Centre, Australia
    Active, not recruiting
    Last update posted :
    03/18/2024
    Initiation :
    09/29/2022
    Primary completion :
    08/03/2024
    Completion :
    12/01/2026
    AR
    177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors (NCT05475210)
    Phase 1
    Molecular Targeting Technologies, Inc.
    Recruiting
    Last update posted :
    03/13/2024
    Initiation :
    06/18/2022
    Primary completion :
    12/31/2024
    Completion :
    03/30/2025
    SSTR
    |
    SSTR Expression
    |
    EBTATE
    Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide (PROMENADE) (NCT04997317)
    Phase 1
    University Hospital, Basel, Switzerland
    Recruiting
    Last update posted :
    03/12/2024
    Initiation :
    04/21/2021
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    SSTR
    |
    SSTR Expression
    |
    SOMther (lutetium-177 DOTA satoreotide) • Solucin (177Lu-edotreotide)
    Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. (START-NET) (NCT05387603)
    Phase 3
    Lund University Hospital
    Active, not recruiting
    Last update posted :
    03/08/2024
    Initiation :
    11/01/2022
    Primary completion :
    10/01/2025
    Completion :
    10/01/2025
    SSTR
    |
    SSTR Expression
    |
    capecitabine • Solucin (177Lu-edotreotide)
    A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan (NCT00577278)
    Phase 2
    City of Hope Medical Center
    Completed
    Last update posted :
    02/16/2024
    Initiation :
    10/03/2007
    Primary completion :
    05/30/2019
    Completion :
    12/14/2023
    CD20
    |
    Rituxan (rituximab) • sirolimus • melphalan • fludarabine IV • Zevalin (ibritumomab tiuxetan)
    A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours (NCT01876771)
    Phase 2
    AHS Cancer Control Alberta
    Recruiting
    Last update posted :
    01/30/2024
    Initiation :
    04/29/2014
    Primary completion :
    12/01/2033
    Completion :
    12/01/2033
    SSTR • CHGA
    |
    SSTR positive
    |
    Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)
    Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver (NCT05610826)
    Phase 1/2
    University of Chicago
    Recruiting
    Last update posted :
    01/29/2024
    Initiation :
    03/07/2023
    Primary completion :
    02/01/2027
    Completion :
    02/01/2027
    SSTR2
    |
    SSTR2 expression
    |
    Lutathera (lutetium Lu 177 dotatate)
    Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation (NCI-V02-1691) (NCT00031642)
    Phase 1/2
    University of Nebraska
    Completed
    Last update posted :
    12/27/2023
    Initiation :
    01/01/2002
    Primary completion :
    11/01/2005
    Completion :
    03/01/2008
    CD20
    |
    Rituxan (rituximab) • Zevalin (ibritumomab tiuxetan)
    Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications (NCT06121271)
    Phase 2
    University College, London
    Not yet recruiting
    Last update posted :
    12/07/2023
    Initiation :
    12/18/2023
    Primary completion :
    11/06/2027
    Completion :
    11/06/2027
    SSTR
    |
    SSTR positive • SSTR Expression
    |
    Lutathera (lutetium Lu 177 dotatate)
    Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE) (NCT03049189)
    Phase 3
    ITM Solucin GmbH
    Active, not recruiting
    Last update posted :
    11/30/2023
    Initiation :
    02/02/2017
    Primary completion :
    12/01/2024
    Completion :
    12/01/2029
    SSTR
    |
    SSTR positive
    |
    everolimus • Solucin (177Lu-edotreotide)
    Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma (NCT02320292)
    Phase 3
    Mayo Clinic
    Completed
    Last update posted :
    11/15/2023
    Initiation :
    02/11/2015
    Primary completion :
    02/28/2021
    Completion :
    11/09/2023
    BCL2 • B2M
    |
    BCL2 mutation
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • Zevalin (ibritumomab tiuxetan) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar)
    Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. (LEVEL) (NCT05918302)
    Phase 3
    Grupo Espanol de Tumores Neuroendocrinos
    Recruiting
    Last update posted :
    11/02/2023
    Initiation :
    10/27/2023
    Primary completion :
    03/01/2028
    Completion :
    07/01/2028
    SSTR
    |
    everolimus • Solucin (177Lu-edotreotide)
    177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer (NCT05603559)
    Phase 1
    Peking Union Medical College Hospital
    Completed
    Last update posted :
    10/23/2023
    Initiation :
    01/01/2023
    Primary completion :
    09/05/2023
    Completion :
    10/04/2023
    FOLH1
    |
    FOLH1 expression • FOLH1 overexpression
    |
    177Lu-P17-087 • 177Lu-P17-088
    "Receptor Radionuclide Therapy With 177Lu-DOTATOC (LUFOR) (NCT06045260)
    Phase 2
    Istituto Scientifico Romagnolo per lo Studio e ...
    Not yet recruiting
    Last update posted :
    09/21/2023
    Initiation :
    10/01/2023
    Primary completion :
    02/01/2025
    Completion :
    01/01/2027
    SSTR2
    |
    SSTR2 positive
    |
    Solucin (177Lu-edotreotide)
    Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma (NCT00006695)
    Phase 2
    University of Nebraska
    Completed
    Last update posted :
    09/01/2023
    Initiation :
    04/01/2000
    Primary completion :
    09/01/2005
    Completion :
    12/16/2014
    CD20 • CD34
    |
    cytarabine • etoposide IV • carmustine • melphalan • Bexxar (iodine I 131 tositumomab) • captisol-enabled melphalan
    A Dose Finding Study to Treat Bone Tumor(s) (NCT06008483)
    Phase 1
    QSAM Therapeutics, Inc.
    Recruiting
    Last update posted :
    08/23/2023
    Initiation :
    04/05/2022
    Primary completion :
    04/05/2024
    Completion :
    11/01/2024
    CD34
    |
    CycloSam (samarium-153 DOTMP)
    Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer (NCT04886986)
    Phase 1/2
    Weill Medical College of Cornell University
    Suspended
    Last update posted :
    08/21/2023
    Initiation :
    06/30/2021
    Primary completion :
    12/24/2024
    Completion :
    12/27/2027
    CYP17A1
    |
    lutetium zadavotide guraxetan (PNT2002) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma (NCT01484093)
    Phase 1/2
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    08/16/2023
    Initiation :
    11/29/2011
    Primary completion :
    08/11/2023
    Completion :
    08/11/2023
    CCND1
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Bexxar (iodine I 131 tositumomab)